Abstract. Chemoresistance is one of the main obstacles to successful cancer therapy and is frequently associated with multidrug resistance (MDR). One of the most studied mechanisms of MDR is the high expression of ATP-binding cassette (ABC) transporters. Here, we demonstrated that NP-1250, an ABCG2 inhibitor, induced apoptotic cell death in ABCG2-overexpressing multidrug-resistant MCF7/ mitoxantrone-resistant (MX) human breast carcinoma cells via a caspase-independent pathway. Incubation of MCF7/MX cells with NP-1250 significantly reduced cell viability, while NP-1250 had little effect on the viability of drug-sensitive MCF7/wild-type cells. Although the target molecules of NP-1250 in cell death remain unknown, investigation of NP-1250 will aid in the elucidation of the molecular mechanism of drug resistance and NP-1250 may become a new therapy for MDR cancers.
Introduction
A frequent problem in cancer chemotherapy is the development of multidrug resistance (MDR) which renders tumors unresponsive to a diverse array of compounds. There are a number of mechanisms by which a cell can acquire MDR, one of the most common being overexpression of members of the ATP-binding cassette (ABC) transporter family. This is a group of plasma membrane proteins that actively extrude a broad range of substrates from cells. They are predominantly found in areas such as the epithelial cells of the intestine, hepatocytes, capillary epithelial cells of the blood-brain barrier, and in various stem cells where the physiological role of these ATPase efflux 'pumps' is to protect cells from damage by rapidly extruding xenobiotics (1) . Unfortunately, their unwanted expression in tumor cells can lead to chemotherapy resistance in these cells (2) .
Most research concerning ABC transporter-overexpressing MDR cancer cells have focused on molecules or signaling pathways that regulate expression of these transporters (3, 4) , and a few potential therapeutic target molecules have been identified. In recent years, it has been reported that suppression of ABC transporters inhibits cancer cell prolifer ation, particularly in transporter-overexpressing MDR cancer cells (5, 6) . However, there are no reports concerning the relationship between inhibition of ABC transporters and cell death.
In the present study, we demonstrated that treatment with NP-1250, an ABCG2 inhibitor, alone induced apoptotic cell death via a caspase-independent pathway in MDR MCF7 breast cancer cells (MCF7/MX). MCF7/MX cells (1) have the MDR phenotype characterized by high levels of the ABCG2 transporter. We speculated that NP-1250 would have an effect on molecules involved in growth and survival, whose expression levels have been elevated in the process of acquiring resistance to anticancer drugs. Using a proteomics approach, we identified three candidate molecules: peroxiredoxin-2,
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protein disulfide-isomerase A4 and prohibitin-2. These molecules may be potential candidates for the treatment of MDR cancers. (8) .
Materials and methods

Materials
Evaluation of the inhibitory effect on the ABCG2 transporter.
To evaluate ABCG2-NP-1250 interaction, plasma membrane vesicles prepared from ABCG2-expressing Sf9 cells were incubated with [ 3 H]methotrexate (MTX). Transport into the vesicles was measured by counting the radioactivity remaining on the filter of MultiScreen plates, as previously described (9) .
Cell viability assay. To evaluate the effectiveness of NP-1250 in overcoming ABCG2-mediated drug resistance, Flp-In-293/ABCG2 and MCF7/MX cells were incubated with anticancer drug SN-38 and NP-1250, and the cell viabilities were measured.
Tumor cells were seeded in 96-well plates. After 24 h, the medium was replaced with medium containing different concentrations of NP-1250 in triplicate. After a 72-h incubation at 37˚C, cell viability was determined at the indicated times, as previously described (10) .
TUNEL staining. MCF7/WT and MCF7/MX cells were seeded in 35-mm glass-bottom dishes. After 24 h, the medium was replaced with medium containing 10, 20 or 40 µM of NP-1250. After a 48-h incubation at 37˚C, TUNEL staining was performed as previously described (10 Real-time PCR. Real-time PCR was carried out using Fast SYBR-Green Master Mix (4385612, Applied Biosystems, Life Technologies Corp., Carlsbad, CA, USA) using a 7500 Fast Real-Time PCR system (Applied Biosystems). All primers used for real-time PCR are described in Table I . PCR was carried out with an initial 20-sec denaturation at 95˚C followed by 40 cycles of PCR (3 sec at 95˚C and 30 sec at 60˚C). Reactions were performed in triplicate for three biological replicates, and the amount of each cDNA was normalized to GAPDH gene expression. Melt-curve analysis was performed to ensure that the mRNA-specific fragments were amplified and data were analyzed using the standard curve method.
Immunofluorescence staining of ABCG2. Cells were fixed in 4% paraformaldehyde, permeabilized with 0.2% Triton X-100, and blocked with 1% bovine serum albumin and 10% normal goat serum in phosphate-buffered saline (PBS). Incubation with primary monoclonal antibody for ABCG2 (ALX-801-029; Wako, Osaka, Japan) at a dilution of 1:200 was carried out overnight at 4˚C, followed by incubation with the Alexa Fluor-conjugated secondary antibody (A11001; Molecular Probes, Inc., Carlsbad, CA, USA) for 1 h at room temperature. Immunofluorescence was detected and analyzed using a Leica TCS SP5 Laser Scanning Confocal Microscope system.
Western blot analysis. Cells were washed two times with PBS, harvested by scraping from the culture dishes in lysis buffer and collected. Protein concentrations were determined using the DC protein assay kit according to the manufacturer's instructions (500-0116; Bio-Rad, Hercules, CA, USA). Equal amounts of proteins were denatured by boiling and subjected to SDS-polyacrylamide gel electrophoresis. The separated proteins were transferred to polyvinylidene difluoride membranes. The membranes were incubated overnight at 4˚C with primary polyclonal antibody at a dilution of 1:1000 for caspase-3, cleaved-PARP, cleaved-caspase-7 or cleavedcaspase-9 (9665, 9541, 9491, 9501; Cell Signaling Technology, Beverly, MA, USA). Membranes were then incubated with goat anti-rabbit IgG-HRP secondary antibody for 1 h at room temperature and visualized using an enhanced chemiluminescence detection system.
Proteomics SDS-PAGE and detection by MS compatible silver staining.
MCF7/WT and MCF7/MX cells were fractionated using the ProteoExtract ® Subcellular Proteome Extraction kit (Merck KGaA, Darmstadt, Germany). Protein samples (5 µg) were separated by SDS-PAGE. Upon completion, the gel was transferred to a clean and dry glass chamber for silver staining using the PlusOne Silver Staining kit, Protein (GE Healthcare, Hino, Japan).
Identification of protein.
In-gel digestion using trypsin was performed as previously described (11) . The tryptic peptides were used for identification of proteins by mass spectrometry. The digested peptides were analyzed using a nanoflow LC-MS/MS system with a direct nanoflow LC system (DiNa; KYA Technologies, Tokyo, Japan) and a LTQ Orbitrap XL-ETD mass spectrometer (Thermo Fisher Scientific, Inc., Waltham, MA, USA). Data were searched against NCBI human sequence database using Mascot (Matrix Science, Ltd., London, UK).
Statistical analysis.
The results are expressed as means ± SD. Each value represents the mean ± SD of two or three independent experiments. One-way analysis of variance (ANOVA) with Dunnett multiple comparison test and t-test were performed, and P<0.01 was considered to indicate a statistically significant difference.
Results and Discussion
NP-1250 is an ABCG2 inhibitor and treatment alone reduces the cell viability of ABCG2-overexpressing MCF7/MX cells.
We measured ATP-dependent [ 3 H]MTX transport in plasma membrane vesicles, prepared from ABCG2-expressing Sf9 cells, in the presence of a potassium salt of NP-1250. Potassium salt of NP-1250 inhibited ABCG2-mediated MTX transport in a dose-dependent manner (Fig. 1A) . This degree of inhibition was comparable to gefitinib (9), suggesting that NP-1250 is a powerful ABCG2 inhibitor. To examine whether NP-1250 overcomes ABCG2-mediated resistance, the cytotoxic effect of ABCG2-substrate SN-38 in the presence of NP-1250 on Flp-In-293/ABCG2 cells was measured. NP-1250 dosedependently reversed SN-38 resistance in Flp-In-293/ABCG2 cells (Fig. 1B) . We then evaluated NP-1250 on MCF7/MX cells, a mitoxantrone-resistant cell line in which ABCG2 was amplified and overexpressed ( Fig. 2) by chronic exposure to mitoxantrone. Differing from our expectation, NP-1250 exhibited no reversing effect on MCF7/MX cells at concentrations <20 µM (Fig. 1C) . Notably, 20 µM of NP-1250 inhibited cell viability with a very low dose of SN-38. These results suggest that ABCG2-inhibitor NP-1250 itself may have a cytotoxic effect.
NP-1250 induces apoptotic cell death in MCF7/MX cells.
We compared the chemosensitivity to NP-1250 of drug-sensitive MCF7/WT cells and multidrug-resistant MCF7/MX cells by examining the cell viability and cell morphological changes. We discovered that NP-1250 alone reduced the cell viability of MCF7/MX cells, notably, more than that of MCF7/WT cells (Fig. 3A) . For the cell morphological study, the number of MCF7/MX cells was significantly less than the number of cells in the control and the adherent cells displayed large vacuoles in the cytoplasm, exhibited atrophic changes or were almost dying (Fig. 3B) . In contrast, little change was observed in MCF7/WT cells after a 72-h treatment (Fig. 3B) . To confirm these initial observations, we analyzed apoptosis by TUNEL assay and phosphatidylserine (PS) externalization. After a 48-h treatment with NP-1250, in MCF7/MX cells, the number of TUNEL-positive cells was elevated (Fig. 3C ) and the TUNELpositive rate was significantly increased in a dose-dependent manner (Fig. 3D) . Apoptotic cell death observed in the MCF7/ MX cells upon treatment with NP-1250 was further confirmed by determining Annexin V binding to PS translocated from the inner to the outer membrane surface of the plasma membrane, a hallmark of early stage apoptosis (Fig. 3E) .
NP-1250-induced cell death is 'caspase-independent apoptosis'.
After 48 h of treatment with NP-1250, cleavage of PARP was detected using an antibody recognizing the 89-kDa fragment (Fig. 4A) . Although PARP is a well-known substrate of caspases, particularly caspase-3 and caspase-7, MCF7 cells do not express caspase-3 due to the deletion of 125 nucleotides in the CASP-3 mRNA (12) . We confirmed the lack of caspase-3 protein in these MCF7/WT and MCF7/MX cells (data not shown). We, therefore, examined whether caspase-7 and caspase-9 were cleaved prior to cleavage of PARP, but we did not detect either one (Fig. 4A) . To further ascertain whether NP-1250-induced apoptosis of MCF7/MX cells was caspase-dependent or -independent, MCF7/MX cells were pretreated with a caspase inhibitor prior to NP-1250 treatment, and cleavage of PARP was subsequently examined. Pretreatment with the pan-specific inhibitor completely abolished the cleavage of PARP, and the pharmacological inhibitor specific for caspase-3/7 also showed a significant inhibition of the cleavage of PARP (Fig. 4B) . Under the same experimental conditions, pretreatment of MCF7/MX cells with these inhibitors did not block the production of apoptotic cells (Fig. 4C) . These results suggest that caspases, which cleave PARP, are cleaved and activated upon exposure of MCF7/MX cells to NP-1250 but that this is not the main apoptotic cascade in the death of MCF7/MX cells.
To evaluate the effects of NP-1250 on other MDR cell lines that exhibit increased expression of ABC transporters, we treated several MDR cell lines and their drug-sensitive parental cell lines with NP-1250. We did not observe growth inhibition by NP-1250 in any of the cell lines (data not shown). We also treated several other cancer cell lines, specifically human hepatocellular carcinoma cell line HuH7, human cervical adenocarcinoma cell line HeLa and human mesothelioma cell lines H226 and MESO4, with NP-1250, but we did not confirm any effect (data not shown). Taken together, these results suggest that the antiproliferative/apoptotic effect of NP-1250 may be limited to MCF7/MX cells.
Search for target proteins by proteomics.
There are no reports relating inhibition of ABC transporters to cell death, therefore, we speculated that NP-1250 may have other targets in MCF7/ MX cells.
We excised several bands that were observed in the protein electrophoretograms of MCF7/MX cells. As a control, we also excised the band that appeared to be ABCG2, ~74 kDa, as observed in the membrane/organelle fraction of MCF7/MX cells. ABCG2 was identified in this band with a Mascot score of 192, thus we excluded proteins whose Mascot scores were <100. We also excluded proteins observed at positions >15 kDa different from their original molecular weight. Candidate proteins that passed our identification criteria are listed in Table II . We selected molecules preferentially involved in cell growth and survival from these proteins and performed realtime PCR to confirm whether the expression of genes encoding these proteins was increased in the MCF7/MX cells when compared to the MCF7/WT cells. Among the 46 proteins, we analyzed the gene expression of 22 proteins, including ABCG2. Three of these proteins, peroxi redoxin-2 (PRDX2), protein disulfide-isomerase A4 (PDIA4) and prohibitin-2 (PHB2), showed significantly elevated mRNA expression in MCF7/MX cells compared to the expression levels in MCF7/ WT cells (Fig. 5) . PDIA4 is a protein disulfide isomerase (PDI), an enzyme that catalyzes disulfide formation and isomerization and a chaperone that inhibits aggregation (13) and a member of a large family of dithiol/disulfide oxidoreductases, the thioredoxin superfamily. While it has been reported that PDI shows an inverse correlation with resistance (14), Liu et al reported that increased expression of PDI was found in multidrug-resistant MCF7/AdVp3000 cells when compared to MCF7 cells (15) . PHB2, known as a repressor of estrogen receptor (ER) activity, has been shown to interact with and inhibit the transcriptional activity of the ER (16) . While PHB2 has been implicated in a previously uncharacterized pathway of multidrug resistance in Caenorhabditis elegans (17), Keenan et al found that PHB2 was inversely correlated with resistance in a squamous lung cancer cell line (14) . PRDX2 has been previously known as a natural killer-enhancing factor B (18) and is induced by various oxidative stimuli. It plays an important protective role against oxidative radical damage by reactive oxygen and nitrogen species (19) . Its expression is correlated with resistance to apoptosis induced by radiation therapy or anticancer drugs (20) , highlighting the potential clinical importance of PRDX2 in chemotherapy resistance in cancer. However, the association of PRDX2 and MCF7/MX cells has not been previously reported. Thus further studies, such as knockdown experiments, are warranted.
In the present study, NP-1250 showed no cytostatic effect on other MDR cancer cell lines. However, it may be effective against specific tumors that are clinically similar to MCF7/MX cells and there is still a possibility that it may lead to the identification of new therapeutic molecules for MDR cancers.
